Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Stayble Therapeutics AB, a Swedish biotechnology company specializing in injectable treatments for chronic back pain, has called an extraordinary general meeting on May 7 to vote on a proposal for voluntary liquidation. The board's recommendation follows unsuccessful efforts to secure partnerships or financing for its…
Share This Article
Ready-to-post copy includes the article link.
Stayble Therapeutics to Seek Shareholder Approval for Liquidation and IP Asset Sale Stayble Therapeutics AB, a Swedish biotechnology company specializing in injectable treatments for chronic back pain, has called an extraordinary general meeting on May 7 to vote on a proposal for voluntary liquidation.... Read the full IIPLA article: https://iipla.org/news/stayble-therapeutics-to-seek-shareholder-approval-for-liquidation-and-ip-asset-sale